{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"95% binomial confidence intervals calculated.","groups":[{"description":"Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nalisertib: Given PO\n\nrituximab: Given IV\n\nlaboratory biomarker analysis: Laboratory correlative studies will be performed","id":"OG000","title":"Cohort A (Alisertib, Rituximab)"},{"description":"Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nalisertib: Given PO\n\nrituximab: Given IV\n\nlaboratory biomarker analysis: Laboratory correlative studies will be performed","id":"OG001","title":"Cohort B (Alisertib, Rituximab)"}],"populationDescription":"Data were not collected from the single participant in the \"Cohort A (Alisertib, Rituximab)\" Arm/Group therfore the 95% Confidence Interval was incalculable due to an insufficient number of events","reportingStatus":"POSTED","timeFrame":"12 weeks (4 courses)","title":"Overall Response Rate (ORR)","type":"SECONDARY"}